Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients

Table 2

Changes in biochemical markers during the study period.

	Baseline	6 months	12 months	18 months^a	Percentage change^b	value
CTx (ng/mL)	0.62 ± 0.21	0.23 ± 0.17	0.22 ± 0.12	0.30 ± 0.18	−51.6%	<0.001
Calcium (mg/dL)	9.1 ± 0.7	9.0 ± 0.6	9.1 ± 0.4	9.0 ± 0.8	−1.1%	0.542
Phosphorous (mg/dL)	3.4 ± 0.5	3.5 ± 0.6	3.4 ± 0.4	3.5 ± 0.6	2.9%	0.381
25(OH)D (ng/mL)	30.3 ± 10.0	32.4 ± 11.1	32.3 ± 11.1	31.4 ± 11.3	3.6%	0.494

CTx, cross-linked C-terminal telopeptide of type 1 collagen; 25(OH)D, 25-hydroxyvitamin D; ^ameasured 6 months after the total of 3 denosumab injections administered at 6-month intervals; ^bpercentage change of baseline versus 18 months; value by the one-way ANOVA and post-hoc analysis; Dunnett’s method was applied for the post-hoc analysis; compared with the baseline.